請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/40708完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳信銘(Hsien-Min Chen) | |
| dc.contributor.author | Chien-Fu Tseng | en |
| dc.contributor.author | 曾建福 | zh_TW |
| dc.date.accessioned | 2021-06-14T16:56:50Z | - |
| dc.date.available | 2018-07-30 | |
| dc.date.copyright | 2008-08-13 | |
| dc.date.issued | 2008 | |
| dc.date.submitted | 2008-07-30 | |
| dc.identifier.citation | Acker, T., A. Diez-Juan, et al. (2005). 'Genetic evidence for a tumor suppressor role of HIF-2alpha.' Cancer Cell 8(2): 131-41.
Aebersold, D. M., P. Burri, et al. (2001). 'Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer.' Cancer Res 61(7): 2911-6. Agani, F. H., P. Pichiule, et al. (2000). 'The role of mitochondria in the regulation of hypoxia-inducible factor 1 expression during hypoxia.' J Biol Chem 275(46): 35863-7. Agarwal, B., C. V. Rao, et al. (1999). 'Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac.' Gastroenterology 117(4): 838-47. Ahmedin Jemal, Rebecca Siegel, et al. (2008). 'Cancer statistics, 2008.' CA Cancer J Clin 58: 71-96 Amano, H., I. Hayashi, et al. ( 2003). 'Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth.' J Exp Med. 197: 221-232. Annika, U., A. RESSEL, et al. (2003). 'The hypoxia-inducible factor-1α is a negative factor for tumor therapy.' Oncogene 22( no21, pp.): 3213-3220 Ashkenazi, A. and V. M. Dixit (1998). 'Death receptors: signaling and modulation.[see comment].' Science 281(5381): 1305-8. Batlle, A. M. (1993). 'Porphyrins, porphyrias, cancer and photodynamic therapy--a model for carcinogenesis.' J.Photochem.Photobiol.B. 20: 5-22. Becker, C. M., N. Rohwer, et al. (2008). '2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis.' American Journal of Pathology 172(2): 534-44. Belaiba, R. S., S. Bonello, et al. (2007). 'Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells.' Molecular Biology of the Cell 18(12): 4691-7. Berberat, P. O., Z. Dambrauskas, et al. (2005). 'Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment.' Clin Cancer Res 11(10): 3790-8. Birner, P., M. Schindl, et al. (2001). ' Expression of hypoxia-inducible factor-1 in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy.' Clin Cancer Res 7(1661-8): 1661. Blancher, C., J. Moore, et al. (2001). 'Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.' Cancer Res 61: 7349-55. Bos, R., P. van der Groep, et al. (2003). 'Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.' Cancer 97(6): 1573-81. Bos, R., H. Zhong, et al. (2001). 'Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis.' J Natl Cancer Inst 93(4): 309-14. Brahimi-Horn, C. and J. Pouyssegur (2006). 'The role of the hypoxia-inducible factor in tumor metabolism growth and invasion.' Bull Cancer 93(8): E73-80. Brennan, P. A., N. Mackenzie, et al. (2005). 'Hypoxia-inducible factor 1alpha in oral cancer.' J Oral Pathol Med 34(7): 385-9. Brown, J. M. (2002). 'Tumor microenvironment and the response to anticancer therapy.' Cancer Biol Ther 1(5): 453-8. Brown, J. M. (2007). 'Tumor hypoxia in cancer therapy.' Methods in Enzymology 435: 297-321. Bruick, R. K. (2000). 'Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia.' Proceedings of the National Academy of Sciences of the United States of America 97(16): 9082-7. Brunelle, J. K. and N. S. Chandel (2002). 'Oxygen deprivation induced cell death: an update.' Apoptosis 7(6): 475-82. Buchler, P., H. A. Reber, et al. (2003). 'Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer.' Pancreas 26(1): 56-64. Bunn, H. F. and R. O. Poyton (1996). 'Oxygen sensing and molecular adaptation to hypoxia.' Physiological Reviews 76(3): 839-85. Carmeliet, P. and E. M. Conway (2001). 'Growing better blood vessels.[comment].' Nature Biotechnology 19(11): 1019-20. Carmeliet, P., Y. Dor, et al. (1998). 'Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis.' Nature 394(6692): 485-90. Carmeliet, P., Y. Dor, et al. (1998). 'Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis.[erratum appears in Nature 1998 Oct 1;395(6701):525 Note: Keshet E [corrected to Keshert E]].' Nature 394(6692): 485-90. Chen, H. M., C. T. Chen, et al. (2004). 'Successful treatment of oral verrucous hyperplasia with topical 5-aminolevulinic acid-mediated photodynamic therapy.' Oral Oncol 40(6): 630-7. Chen, H. M., C. T. Chen, et al. (2005). 'Successful treatment of an extensive verrucous carcinoma with topical 5-aminolevulinic acid-mediated photodynamic therapy.' J Oral Pathol Med 34(4): 253-6. Chen, M. and J. Wang (2002). 'Initiator caspases in apoptosis signaling pathways.' Apoptosis 7: 313-319. Chen, Z. and Z. C. Han (2008). 'STAT3: a critical transcription activator in angiogenesis.' Medicinal Research Reviews 28(2): 185-200. Choi, K. S., M. K. Bae, et al. (2003). 'Hypoxia-induced angiogenesis during carcinogenesis.' Journal of Biochemistry & Molecular Biology 36(1): 120-7. Chun, Y. S., E. J. Yeo, et al. (2001). 'Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells.' Biochem Pharmacol 61(8): 947-54. Crews, S. T. (1998). 'Control of cell lineage-specific development and transcription by bHLH-PAS proteins ' Genes & Dev. 12( 5): 607-620. Daniel M. Aebersold, P. B., Karl T. Beer, Jean Laissue, Valentin Djonov, Richard H. Greiner, and and G. L. Semenza2 (2001). 'hypoxia-inducible factor-1a: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer.' Cancer Research 61( April 1): 2911-2916. Daniel M. Aebersold, P. B., Karl T. Beer, Jean Laissue, Valentin Djonov, Richard H. Greiner, and and G. L. Semenza2 (2001). 'hypoxia-inducible factor-1a: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer.' Cancer Research 61( April 1): 2911-2916. Dellas, K., M. Bache, et al. (2008). 'Prognostic impact of HIF-1alpha expression in patients with definitive radiotherapy for cervical cancer.' Strahlentherapie und Onkologie 184(3): 169-74. Department of Health, T. E. Y., Taiwan (2007). 'Cancer registry annual report in Taiwan area.' Ema, M., S. Taya, et al. (1997). 'A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development.' Proc Natl Acad Sci U S A 94(9): 4273-8. Faton, H., M. P. Agani, et al. (2002). 'Role of nitric oxide in the regulation of HIF-1 expression during hypoxia ' Am J Physiol Cell Physiol 283: C178-C186. Fechner, G., G. Muller, et al. (2007). 'Evaluation of hypoxia-mediated growth factors in a novel bladder cancer animal model.' Anticancer Research 27(6B): 4225-31. Feng, C. J., J. B. Guo, et al. (2008). 'Spatio-temporal localization of HIF-1alpha and COX-2 during irradiation-induced oral mucositis in a rat model system.' International Journal of Radiation Biology 84(1): 35-45. Ferrario, A. and C. J. Gomer (2006). 'Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model.' J Environ Pathol Toxicol Oncol 25(1-2): 251-9. Ferrario, A., K. Von Tiehl, et al. (2002). 'Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response.' Cancer Res 62(14): 3956-61. Ferrario, A., K. F. von Tiehl, et al. (2000). 'Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma.' Cancer Res 60(15): 4066-9. Flamme, I., T. Frohlich, et al. (1997). 'HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 alpha and developmentally expressed in blood vessels.' Mech Dev 63(1): 51-60. Folkman, J., E. Merler, et al. (1971). 'Isolation of a tumor factor responsible for angiogenesis.' J.Exp.Med. 133: 275-288. Fong, G. H. (2008). 'Mechanisms of adaptive angiogenesis to tissue hypoxia.' Angiogenesis 11(2): 121-40. Forsythe, J. A., B. H. Jiang, et al. (1996). 'Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1.' Mol Cell Biol 16(9): 4604-13. Galanis, A., A. Pappa, et al. (2008). 'Reactive oxygen species and HIF-1 signalling in cancer.' Cancer Letters 266(1): 12-20. Garth, L. K. P. (2004). 'Hypoxia inducible factor-1 as a cancer drug target ' Mol Cancer Ther. 3: 647-654. Giatromanolaki, A., M. Koukourakis, et al. ( 2001). 'Relation of hypoxia inducible factor 1 and 2 in operable non-small cell lung cancer to angiogenic molecular profile of tumors and survival. .' Br J Cancer 85(881-90). Giatromanolaki, A., M. I. Koukourakis, et al. (2007). 'Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer.' European Journal of Clinical Investigation 37(11): 878-86. Giordano, F. J. and R. S. Johnson (2001). 'Angiogenesis: the role of the microenvironment in flipping the switch.' Current Opinion in Genetics & Development 11(1): 35-40. Goldberg, M., S. Dunning, et al. (1988). 'Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein.' Science (Wash DC) 242: 1412-1415. Gorlach, A. and T. Kietzmann (2007). 'Superoxide and derived reactive oxygen species in the regulation of hypoxia-inducible factors.' Methods in Enzymology 435: 421-46. Griffiths, L., K. Binley, et al. (2000). 'The macrophage-a novel system to deliver gene therapy to pathological hypoxia.' Gene Ther 777: 255-62. Gu, G. J., Y. P. Li, et al. (2008). 'Mechanism of ischemic tolerance induced by hyperbaric oxygen preconditioning involves upregulation of hypoxia-inducible factor-1alpha and erythropoietin in rats.' Journal of Applied Physiology 104(4): 1185-91. Gu, Y. Z., S. M. Moran, et al. (1998). 'Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha.' Gene Expr 7(3): 205-13. Gupta, A. and J. Ryder (2003). 'Photodynamic therapy and topical aminolevulinic acid: an overview.' Am J Clin Dermatol 4(10): 699-708. Guzy, R., B. Hoyos, et al. (2005). 'Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing.' Cell Metab 1(6): 401-8. H E Ryan, J. L., and R S Johnson (1998). 'HIF-1 alpha is required for solid tumor formation and embryonic vascularization.' EMBO J 17(11): 3005–3015. Ha, C. H., A. M. Bennett, et al. (2008). 'A novel role of vascular endothelial cadherin in modulating c-Src activation and downstream signaling of vascular endothelial growth factor.' Journal of Biological Chemistry 283(11): 7261-70. Hasina, R. and M. W. Lingen (2001). 'Angiogenesis in oral cancer.' Journal of Dental Education 65(11): 1282-90. Hebert, C., K. Norris, et al. (2006). 'Hypoxia-inducible factor-1alpha polymorphisms and TSC1/2 mutations are complementary in head and neck cancers.' Mol Cancer 5: 3. Herschman, H. R. (1994). 'Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. .' Cancer Metastasis Rev. 13: 241-256. Hogenesch, J. B., W. K. Chan, et al. (1997). 'Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway.' J Biol Chem 272(13): 8581-93. Horree, N., A. J. Groot, et al. (2008). 'HIF-1A gene mutations associated with higher microvessel density in endometrial carcinomas.' Histopathology 52(5): 637-9. Howe, L. R., K. Subbaramaiah, et al. (2001). 'Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.' Endocr.Relat Cancer. 8: 97-114. Huang, L. and H. Bunn (2003). 'Hypoxia-inducible factor and its biomedical relevance. .' J Biol Chem 278: 19575-8. Huang, L. E. (2008). 'Carrot and stick: HIF-alpha engages c-Myc in hypoxic adaptation.' Cell Death & Differentiation 15(4): 672-7. Huang LE, Arany Z, et al. (1996). 'Activation of hypoxiainducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit.' J Biol Chem 271: 32253-32259. Huang, X. Z., J. Wang, et al. (2008). 'Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: the mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1.' Cancer Biology & Therapy 7(3): 468-75. HW, K. (1976). 'A statistical study on oral carcinomas in Taiwan with emphasis on the relationship with betel nut chewing:A preliminary report ' J Formosan Med Assoc. 75: 497-505. Jain, R. K. (2001). 'Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.' Nat Med 7(9): 987-9. Ji, Z., G. Yang, et al. (2006). 'Induction of hypoxia-inducible factor-1alpha overexpression by cobalt chloride enhances cellular resistance to photodynamic therapy.' Cancer Lett 244(2): 182-9. Juarranz, A., P. Jaen, et al. (2008). 'Photodynamic therapy of cancer. Basic principles and applications.' Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societes & of the National Cancer Institute of Mexico 10(3): 148-54. Kakiuchi, Y., S. Tsuji, et al. ( 2002). 'Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis.' Cancer Res. 62: 1567-1572. Kalgutkar, A. S. and Z. Zhao ( 2001). ' Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, anti-inflammatory drugs with potential utility as anti-cancer agents. .' Curr Drug Targets 2: 79-101. Kallio, P. J., I. Pongratz, et al. (1997). 'Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor.' Proc Natl Acad Sci U S A 94(11): 5667-72. Karamouzis, M. V. and A. G. Papavassiliou (2004). 'COX-2 inhibition in cancer therapeutics: a field of controversy or a magic bullet?' Expert Opin Investig Drugs 13(4): 359-72. Kennedy, J. C., S. L. Marcus, et al. (1996). 'Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): mechanisms and clinical results.' J Clin Laser Med Surg 14(5): 289-304. Kietzmann, T. and A. Gorlach (2005). 'Reactive oxygen species in the control of hypoxia-inducible factor-mediated gene expression.' Semin Cell Dev Biol 16(4-5): 474-86. Ko, Y. C., Y. L. Huang, et al. (1995). 'Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan.' Journal of Oral Pathology & Medicine 24(10): 450-3. Konstantinopoulos, P. A., G. P. Vandoros, et al. (2007). 'EGF-R is expressed and AP-1 and NF-kappaB are activated in stromal myofibroblasts surrounding colon adenocarcinomas paralleling expression of COX-2 and VEGF.' Cellular Oncology 29(6): 477-82. Koukourakis, M. I., A. Giatromanolaki, et al. (2001). 'Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy.' Cancer Res 61(5): 1830-2. Krishnamachary, B., S. Berg-Dixon, et al. (2003). 'Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1.' Cancer Res 63(5): 1138-43. Kung AL, W. S., Klco JM, Kaelin WG. Livingston DM ( 2000). 'Suppression of tumor growth through disruption of hypoxiainducible transcription. .' Nat Med 6: 1335-40. Lam, S. Y., G. L. Tipoe, et al. (2008). 'Differential expressions and roles of hypoxia-inducible factor-1alpha, -2alpha and -3alpha in the rat carotid body during chronic and intermittent hypoxia.' Histology & Histopathology 23(3): 271-80. Lando, D., D. J. Peet, et al. (2002). 'FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor.' Genes Dev 16(12): 1466-71. Lando, D., D. J. Peet, et al. (2002). 'Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch.' Science 295(5556): 858-61. Lee, H. J., J. Lee, et al. (2008). 'Differential induction of heme oxygenase-1 against nicotine-induced cytotoxicity via the PI3K, MAPK, and NF-kappa B pathways in immortalized and malignant human oral keratinocytes.' Journal of Oral Pathology & Medicine 37(5): 278-86. Lee, S. H., M. Y. Lee, et al. (2008). 'Short-period hypoxia increases mouse embryonic stem cell proliferation through cooperation of arachidonic acid and PI3K/Akt signalling pathways.' Cell Proliferation 41(2): 230-47. Leker, R. R., T. Peretz, et al. (1997). 'Vincristine-induced paralytic ileus in Parkinson's disease.' Parkinsonism & Related Disorders 3(2): 109-10. Li, X., Y. Lu, et al. (2008). 'Requirement of hypoxia-inducible factor-1{alpha} down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab.' Molecular Cancer Therapeutics 7(5): 1207-17. Liu, T. and Y. Ba (2008). '[Expression of hypoxia inducible factor-1alpha and BNIP3 in human laryngeal carcinoma and their relationship].' Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi = Journal Of Clinical Otorhinolaryngology, Head, & Neck Surgery 22(3): 112-4. Makino, Y., R. Cao, et al. (2001). 'Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression.' Nature 414(6863): 550-4. Makino, Y., A. Kanopka, et al. (2002). 'Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus.' J Biol Chem 277(36): 32405-8. Manalo, D. J., A. Rowan, et al. (2005). 'Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1.' Blood 105(2): 659-69. Masson, N., C. Willam, et al. (2001). 'Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation.' EMBO Journal 20(18): 5197-206. Matousek, P. (2007). 'Raman signal enhancement in deep spectroscopy of turbid media.' Applied Spectroscopy 61(8): 845-54. Maxwell, P. H., G. U. Dachs, et al. (1997). 'Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth.' Proc Natl Acad Sci U S A 94(15): 8104-9. Mayer, A., M. Hockel, et al. (2008). 'Lack of hypoxic response in uterine leiomyomas despite severe tissue hypoxia.' Cancer Research 68(12): 4719-26. McClintock, D. S., M. T. Santore, et al. (2002). 'Bcl-2 family members and functional electron transport chain regulate oxygen deprivation-induced cell death.' Molecular & Cellular Biology 22(1): 94-104. Melillo, G. (2007). 'Hypoxia-inducible factor 1 inhibitors.' Methods in Enzymology 435: 385-402. Mitra, S., S. E. Cassar, et al. (2006). 'Photodynamic therapy mediates the oxygen-independent activation of hypoxia-inducible factor 1alpha.' Mol Cancer Ther 5(12): 3268-74. Na X, W. G., Ryan CK, Schoen SR, di'Santagnese PA, Messing EM. (2003). 'Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1α expression in renal cell carcinomas.' J Urol 170: 588-92. Nikolov, R. (1998). 'Alzheimer's disease therapy - an update.' Drug News & Perspectives 11(4): 248-55. Ockaili, R., R. Natarajan, et al. (2005). 'HIF-1 activation attenuates postischemic myocardial injury: role for heme oxygenase-1 in modulating microvascular chemokine generation.' Am J Physiol Heart Circ Physiol 289(2): H542-8. Oda, S., T. Oda, et al. (2008). 'Macrophage migration inhibitory factor activates hypoxia-inducible factor in a p53-dependent manner.' PLoS ONE [Electronic Resource] 3(5): e2215. Oh, J. M., I. J. Ryoo, et al. (2008). 'Hypoxia-inducible transcription factor (HIF)-1 alpha stabilization by actin-sequestering protein, thymosin beta-4 (TB4) in Hela cervical tumor cells.' Cancer Letters 264(1): 29-35. Oosthuyse, B., L. Moons, et al. (2001). 'Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration.' Nat Genet 28: 131-8. Peng, Q., T. Warloe, et al. (1997). '5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges.' Cancer 79(12): 2282-308. Peter, J., C. W. Ratcliffe, et al. (2000). 'Targeting tumors through the HIF system.' Nature Medicine 6: 1315-1316. Postovit, L. M., D. E. Abbott, et al. (2008). 'Hypoxia/reoxygenation: a dynamic regulator of lysyl oxidase-facilitated breast cancer migration.' Journal of Cellular Biochemistry 103(5): 1369-78. Pugh, C. W., J. F. O'Rourke, et al. (1997). 'Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit.' J Biol Chem 272(17): 11205-14. Qingdong Ke, a. M. C. (2006). 'Hypoxia-Inducible Factor-1 (HIF-1) ' Molecular Pharmacology 70: 1469-1480. Ravi, R., B. Mookerjee, et al. (2000). 'Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.' Genes Dev 14(1): 34-44. Reyes, H., S. Reisz-Porszasz, et al. (1992). 'Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor.' Science 256(5060): 1193-5. Ruas, J. L., L. Poellinger, et al. (2002). 'Functional analysis of hypoxia-inducible factor-1 alpha-mediated transactivation. Identification of amino acid residues critical for transcriptional activation and/or interaction with CREB-binding protein.' J Biol Chem 277(41): 38723-30. Ryo Fukuda, B. Kelly, et al. (2003). 'Vascular Endothelial Growth Factor Gene Expression in Colon Cancer Cells Exposed to Prostaglandin E2 Is Mediated by Hypoxia-inducible Factor 1.' Cancer Research 63: 2330-2334. Salceda, S. and J. Caro (1997). 'Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes.' J Biol Chem 272(36): 22642-7. Sartippour, M. R., N. P. Seeram, et al. (2008). 'Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo.' Int J Oncol 32(2): 475-80. Sasabe, E., Y. Tatemoto, et al. (2005). 'Mechanism of HIF-1alpha-dependent suppression of hypoxia-induced apoptosis in squamous cell carcinoma cells.' Cancer Sci 96(7): 394-402. Schaper, W. and I. Buschmann (1999). 'VEGF and therapeutic opportunities in cardiovascular diseases.' Current Opinion in Biotechnology 10(6): 541-3. Schror, K. (1993). 'The effect of prostaglandins and thromboxane A2 on coronary vessel tone--mechanisms of action and therapeutic implications.' Eur Heart J. 14(Suppl I): 34-41. Schuler, M. and D. R. Green (2001). 'Mechanisms of p53-dependent apoptosis.' Biochemical Society Transactions 29(Pt 6): 684-8. Schweitzer, V. G. (1990). 'Photodynamic therapy for treatment of head and neck cancer.' Otolaryngol Head Neck Surg 102(3): 225-32. Schweitzer, V. G. and D. Visscher (1990). 'Photodynamic therapy for treatment of AIDS-related oral Kaposi's sarcoma.' Otolaryngol Head Neck Surg 102(6): 639-49. Semenza, G. L. (1998). 'Hypoxia-inducible factor 1: master regulator of O2 homeostasis.' Curr Opin Genet Dev 8(5): 588-94. Semenza, G. L. (2002). 'HIF-1 and tumor progression: pathophysiology and therapeutics.' Trends Mol Med 8(4 Suppl): S62-7. Semenza, G. L. (2004). 'O2-regulated gene expression: transcriptional control of cardiorespiratory physiology by HIF-1.' J Appl Physiol 96(3): 1173-7; discussion 1170-2. Semenza, G. L., M. K. Nejfelt, et al. (1991). 'Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene.' Proc Natl Acad Sci U S A 88(13): 5680-4. Seno, H., M. Oshima, et al. ( 2002). 'Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc-(Delta716) mouse intestinal polyps.' Cancer Res. 62: 506-511. Solban, N., P. K. Selbo, et al. (2006). 'Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer.' Cancer Res 66(11): 5633-40. Srinivas, V., X. Zhu, et al. (1999). 'Hypoxia-inducible factor 1alpha (HIF-1alpha) is a non-heme iron protein. Implications for oxygen sensing.' J Biol Chem 274(2): 1180. Stark, L., F. Din, et al. (2001). 'Aspirin-induced activation of the NFkB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells.' FASEB J. 15: 1273-75. Steller, H. (1995). 'Mechanisms and genes of cellular suicide.' Science 267(5203): 1445-9. Stukavec, J., L. Horak, et al. (2008). 'Comparison of photodynamic therapy with phthalocyanine and photofrin in human colorectal carcinoma.' Neoplasma 55(2): 127-9. Sui, J., J. Wu, et al. (2008). '[The expression and significance of hypoxia inducible factor-1alpha and microvessed density in human nasopharyngeal carcinoma].' Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi = Journal Of Clinical Otorhinolaryngology, Head, & Neck Surgery 22(6): 269-72. Surazynski, A., S. P. Donald, et al. (2008). 'Extracellular matrix and HIF-1 signaling: the role of prolidase.' International Journal of Cancer 122(6): 1435-40. Tachi, Y., D. Fukui, et al. (2008). 'Changes in angiogenesis-related factors in serum following autologous bone marrow cell implantation for severe limb ischemia.' Expert Opinion on Biological Therapy 8(6): 705-12. Talks KL, T. H., Gatter KC, et al. (2000). 'The expression and distribution of the hypoxia-inducible factors HIF-1 and HIF-2 in normal human tissues, cancers, and tumor-associated macrophages. .' Am J Pathol 157: 411-21. Tegeder, I., J. Pfeilschifter, et al. (2001). ' Cyclooxygenase-independent actions of cyclooxygenase inhibitors.' FASEB J. 15: 2057-2072. Tian, H., S. L. McKnight, et al. (1997). 'Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells.' Genes Dev 11(1): 72-82. Tjwa, M., A. Luttun, et al. (2003). 'VEGF and PIGF: two pleiotropic factors with distinct roles in development and homeostasis.' Cell Tissue Res 314: 5-14. Tsai, J. C., C. P. Chiang, et al. (2004). 'Photodynamic Therapy of oral dysplasia with topical 5-aminolevulinic acid and light-emitting diode array.' Lasers Surg Med 34(1): 18-24. Turini, M. E. and R. N. DuBois (2002). 'Cyclooxygenase-2: a therapeutic target.' Annu Rev Med 53: 35-57. Vergis, R., C. M. Corbishley, et al. (2008). 'Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.' Lancet Oncology 9(4): 342-51. Volm, M. and R. Koomagi (2000). 'Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer.' Anticancer Research 20(3A): 1527-33. Wang, G. L., B. H. Jiang, et al. (1995). 'Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.' Proc Natl Acad Sci U S A 92(12): 5510-4. Wiesener, M. S., H. Turley, et al. (1998). 'Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha.' Blood 92(7): 2260-8. Wijffels, K. I., H. A. Marres, et al. (2008). 'Tumour cell proliferation under hypoxic conditions in human head and neck squamous cell carcinomas.' Oral Oncology 44(4): 335-44. Wouters, B., S. Weppler, et al. (2002). 'Hypoxia as a target for combined modality treatments.' Eur J Cancer. 38 (2): 240-57. Yang, H. and C. Chen (2008). 'Cyclooxygenase-2 in synaptic signaling.' Current Pharmaceutical Design 14(14): 1443-51. Yasuda, M., M. Miyazawa, et al. (2008). 'Expression of hypoxia inducible factor-1alpha (HIF-1alpha) and glucose transporter-1 (GLUT-1) in ovarian adenocarcinomas: difference in hypoxic status depending on histological character.' Oncology Reports 19(1): 111-6. Yee, K. K., K. C. Soo, et al. (2005). 'Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma.' Int J Mol Med 16(6): 993-1002. Yeo, E. J., Y. S. Chun, et al. (2003). 'YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.' J Natl Cancer Inst 95(7): 516-25. Yin, S. (2007). '[The expression and significance of HIF-1alpha and COX-2 in laryngeal squamous cell carcinoma].' Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi = Journal Of Clinical Otorhinolaryngology, Head, & Neck Surgery 21(18): 820-4. Zhang, Y., L. M. Liu, et al. (2007). '[Regulatory role of hypoxia inducible factor-1alpha in the changes of contraction of vascular smooth muscle cell induced by hypoxia].' Zhongguo Wei Zhong Bing Ji Jiu Yi Xue/Chinese Critical Care Medicine/Zhongguo Weizhongbing Jijiuyixue 19(11): 647-51. Zhong, H., A. M. De Marzo, et al. (1999). 'Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases.' Cancer Res 59(22): 5830-5. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/40708 | - |
| dc.description.abstract | 口腔癌的排名有逐年上升的趨勢,年增率高居癌症第一位,死亡率過半。癌症治療的方式多樣化,目地在延長病患壽命,甚至進一步治癒癌症。以手術切除常因造成顏面傷殘及病患心理壓力而放棄,為尋求減少侵犯性治療,進行新興的光動力治療。光動力治療(Photodynamic therapy, PDT)是新興的癌症治療的方式,光動力治療已運用在其它不易手術部位的癌療。光動力治療的藥物也有進一步的改善,先前我們採用新研發的二代光感藥物(photosensitizer) 5-氨基酮戊酸(5-aminolevulinic acid, ALA),ALA光動力治療(5-aminilevulinic acid-based photodynamic therapy, ALA-PDT)證實可用於口腔癌的治療,但路徑仍有待進一步研究,而接受光動力治療時所需要的三要件中的氧氣扮演了重要角色。在細胞中對於氧氣的調節扮演重要的角色的缺氧誘導因子-1α(Hypoxia inducible factor-1α, HIF-1α)蛋白是我們想去探討的因子。HIF-1α的過度表現促進腫瘤細胞的生長與血管增生,也影響癌症的療效,如放射線治療與化學治療效果的降低。光動力治療會產生氧化壓力的機轉,過程中細胞環境中的氧會被消耗,造成缺氧狀態,是否是誘發HIF-1α的過度表現的主因,仍有待進一步證實,缺氧誘導因子-1α(Hypoxia inducible factor-1α, HIF-1α)於人類許多癌腫瘤中有過度表現。目前已經發現HIF-1α蛋白之過度表現與許多腫瘤的侵犯、淋巴結轉移、臨床分期、病人存活率及預後都有顯著相關性,而HIF-1α在光動力的治療中是扮演什麼樣的角色,過去的研究中發現其會進一步促進VEGF的生成,其在光動力治療的情況下是否會影響光動力治療的效果。
本研究利用西方墨點法及免疫組織化學染色法,探討HIF-1α於接受光動力治療的惡性口腔癌細胞CA9-22和SAS之間的差別及13例口腔鱗狀細胞癌(OSCC)病患之間的差別。並以HIF-1α和COX-2的抑制劑,以及活性氧分子抑制劑的治療來觀察其蛋白質表現的情況,後續並加入不同的藥物觀察癌細胞治療效果,探討ALA-PDT的影響。 研究中發現其HIF-1α會隨時間增加而增高,誘導HO-1隨時間的增加及VEGF的上升,對細胞凋亡產生抗性,我們發現,以ALA-PDT來處理SAS及CA9-22細胞,可以造成PARP的水解,證實ALA-PDT引起人類口腔癌細胞死亡的方式為細胞凋亡(apoptosis)。先前研究中發現以4J的ALA-PDT處理CA9-22及40J的ALA-PDT處理SAS並不會改變細胞週期。研究以人類口腔癌細胞株CA9-22和SAS探討ALA-PDT中HIF-1α對治療的影響。研究中發現其HIF-1α會隨時間的增加而增高,同時HO-1和VEGF約隨時間的增長而增高,並證實VEGF會受到HIF-1α的調控,ALA-PDT可能因缺氧狀態及單重態氧自由基,產生兩者互相競爭抗恆而影響療效。光動力治療會誘發HIF-1α的表現,HIF-1α會誘發VEGF和HO-1的表現,以ALA-PDT加上HIF-1α抑制劑及COX-2抑制劑可以減少VEGF和HO-1的生成,並增加光動力治療的療效。 HIF-1α有較高表現的口腔癌細胞中顯示對於ALA-PDT有較高的抗性,主要因其誘導相關的蛋白質表現,並對細胞產生保護機制,在光動力治療合併抗缺氧誘導因子-1α可以增強光動力治療的效果。 | zh_TW |
| dc.description.abstract | In Taiwan, the problem of oral cancer in increasing, the increasing rate was the first of the cancer increasing rate. The death patient rate was over half of patient. The methods of treatment cancer were multiple various methods. The aids are elongation the life of patient and cure the disease. The main strategy of the treatment for oral cancer is surgery, but the facial defect resulting from surgery. Due to reduce the invasive treatment, photodynamic therapy (PDT) has been used in the treatment of many cancers, it is the potential therapy, and its advantage is that there is no significant facial defect. The Photodynamic therapy (PDT) is a kind of new developing treatment for cancer. 5-Aminolevulinic acid (ALA) is a novel photosensitizer for photodynamic therapy. We previously showed ALA-PDT can induce cytotoxicity in oral cancer cells. The mechanism for the ALA-PDT induced cytotoxicity is still unknown. Oxygen is the important quench of the three fundamental elements. The expression of hypoxia-inducible factor-1α (HIF-1α) is the regular of oxygen. Overexpressions of HIF-1α have induced the tumor growth and angiogenesis, and affect the treatment result of the cancer therapy, such as radiotherapy and chemotherapy. The PDT has induced the reactive oxygen species (ROS), in the procedure, the O2 was decreased and due to the hypoxia situation. We want to know if the situation was the main cause. That needs us to research. Overexpression of hypoxia-inducible factor-1α (HIF-1α) has been demonstrated in a variety of human cancers and found to be significantly associated with the tumor invasion, lymph node metastasis, clinical stage, survival rate, and prognosis of these cancers. What role is the HIF-1α in the ALA-PDT? In the past study, we found the expression of VEGF was induced with expression of HIF-1α during hypoxia. How to expression of VEGF in the ALA-PDT?
In this study, the immunohistochemistry, Western blot analysis, and MTA assay will be used to investigate if the expression of HIF-1α correlates with the varied treatment results of PDT. And the expression of HIF-1α in 13 specimens of oral squamous cell carcinoma (OSCC). We were calculated and compared between the specimens. Then we treated the cell lines with ALA-PDT plus the inhibitor of the HIF-1α and the COX-2, free radical inhibitor and multiple drugs to research the expression of protein. In our study, we found the expressions of HIF-1α were increased with time follow, and induced the expressions of HO-1 and VEGF, then reduced the ALA-PDT-induced apoptosis. In CA9-22 and in SAS cell lines, we used the ALA-PDT treatment could induced the apoptosis. Apoptosis induced by ALA-PDT was both time- and dose-dependent. Pretreatment of cells with imidazole and histidine (singlet oxygen inhibitor) reduced the ALA-PDT-induced apoptosis. These results indicated that singlet oxygen was an important mechanism for ALA-PDT-induced apoptosis in cells lines. In the IHC, the expressions of HIF-1α had no significant finding with gender, age, tumor size, involved depth, tumor region and pathology. The expressions of HIF-1α in nucleus had significant different findings about the resistance to the photodynamic therapy. There is higher resistance to ALA-PDT in the lesion with over expression of HIF-1α. The HIF-1α protein maybe induce the target gene and protein expression to protect the cell survive. PDT combination with anti-HIF-1α treatment enhance the response. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-14T16:56:50Z (GMT). No. of bitstreams: 1 ntu-97-R95422026-1.pdf: 2114263 bytes, checksum: 371e07daca0effa720a81235df958cde (MD5) Previous issue date: 2008 | en |
| dc.description.tableofcontents | 謝辭 V
中文摘要 VI ABSTRACT VIII 目錄 XI TABLES AND FIGURE 1 Figure 1 Table 7 CHAPTER I 8 INTRODUCTION 8 BACKGROUND 12 PURPOSES OF THIS STUDY 14 LITERATURE REVIEW 15 CHAPTER II 59 MATERIALS AND METHODS 59 Part 1: Cell and growth medium 59 Part 2: Photodynamic Therapy 59 Part 3: Drug treatment 60 Part 4: Western blot analysis 62 Part 5: Cell viability assay (MTT) 64 Part 6: Immunohistochemical staining for HIF-1α 64 Part 7: Statistical analysis 66 CHAPTER III 68 RESULTS 68 Part 1: The effect of HIF-1α in the treatment oral squamous cell carcinomas with ALA-PDT 68 Part 2: The pathway correlated with the effect of HIF-1α in the ALA-PDT 70 CHAPTER IV 98 Discussion 98 Conclusion 106 CHAPTER V 107 APPENDIX( Abbreviation) 107 REFERENCES 108 | |
| dc.language.iso | en | |
| dc.subject | 口腔癌 | zh_TW |
| dc.subject | 缺氧誘導因子-1α | zh_TW |
| dc.subject | 光動力治療 | zh_TW |
| dc.subject | 細胞凋亡 | zh_TW |
| dc.subject | 5-氨基酮酸 | zh_TW |
| dc.subject | 5-aminolevulinic acid | en |
| dc.subject | oral cancer | en |
| dc.subject | hypoxia-inducible factor-1α | en |
| dc.subject | photodynamic therapy | en |
| dc.subject | apoptosis | en |
| dc.title | 探討缺氧誘導因子-1α在口腔癌經光動力治療的表現 | zh_TW |
| dc.title | Expression of Hypoxia Inducible Factor-1α (HIF-1α) via Photodynamic Therapy in Oral Squamous Cell Carcinoma | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 96-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 郭彥彬(Yen-Ping Kuo),陳中和(Chung-Ho Chen) | |
| dc.subject.keyword | 缺氧誘導因子-1α,光動力治療,細胞凋亡,5-氨基酮酸,口腔癌, | zh_TW |
| dc.subject.keyword | hypoxia-inducible factor-1α,photodynamic therapy,apoptosis,5-aminolevulinic acid,oral cancer, | en |
| dc.relation.page | 119 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2008-07-30 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 臨床牙醫學研究所 | zh_TW |
| 顯示於系所單位: | 臨床牙醫學研究所 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-97-1.pdf 未授權公開取用 | 2.06 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
